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ABSTRACT
The development of antibacterial drugs based on novel chemotypes is essential to the future
management of serious drug resistant infections. We herein report the design, synthesis and
SAR of a novel series of N-ethylurea inhibitors based on a pyridine-3-carboxamide scaffold
targeting the ATPase sub-unit of DNA gyrase. Consideration of structural aspects of the
GyrB ATPase site has aided the development of this series resulting in derivatives that
demonstrate excellent enzyme inhibitory activity coupled to potent Gram positive
antibacterial efficacy.
Keywords: Antibiotics, bacterial resistance, DNA gyrase, pyridine-3-carboxamide, molecular
modelling, de novo design.
Introduction
Due in part to disproportionate prescription of antibiotics during the latter half of the 20
th
century, the past 2 decades have seen the inevitable emergence of bacterial resistance to all
currently available therapeutic agents.[1] Of particular concern are the so-called ‘ESKAPE’
pathogens (multi-drug resistant Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species),
which cause infections associated with elevated rates of morbidity and mortality.[2, 3] The
need for antibiotics based upon novel chemotypes which act upon novel molecular targets has
long been recognised as critical to the future management of the problem. A recent
manifestation of this concept is the ‘ten-by-twenty’ initiative, a gauntlet thrown down by the
Infectious Diseases Society of America (IDSA) to those involved in antimicrobial drug
discovery, urging a more concerted effort with the goal of delivering 10 new antibacterial
drugs by 2020.[4]
DNA gyrase and the structurally homologous enzyme topoisomerase IV (topo IV) are highly
conserved ATP dependant bacterial type IIa topoisomerase enzymes which play an essential
role within bacteria linked to the conservation of chromosomal integrity during DNA
replication and transcription.[5] These enzymes have long been validated as therapeutic drug
targets owing to the commercial and clinical success of members of the fluoroquinolone
antibiotic class (e.g. ciprofloxacin, gemifloxacin) which target the catalytic (GyrA / ParC)
sub-units in a dual-inhibitory fashion.[6] More recently, the development of small molecule
ATPase inhibitors of gyrase (GyrB) and topo IV (ParE), aided by the elucidation of protein-
ligand structures of GyrB, has gained attention as a means to inhibit these classical enzyme
targets in the pursuit of novel antibacterial compounds.[7-10]
Encouraged by these reports, our interest in the discovery of novel ATPase inhibitors of
GyrB / ParE began with the observation that a number of reports in the literature
demonstrated that heterocyclic N-ethylurea derivatives to be conducive with potent dual-
inhibitory ATPase activity coupled to antimicrobial activity.[7, 8, 10, 11]. Notably,
benzimidazol-2-yl-ureas (1), benzathiazol-2-yl-ureas (2), imidazopyridin-2-yl-ureas (3),
triazolopyridine-5-carboxamides (4), isoquinolin-3-yl-ureas (5) and pyridin-3-yl-ureas (6)
reported by groups at Vertex[7], Prolysis
11
, Pfizer[10], Evotec[8], Actelion[12] and
AstraZeneca[13] respectively, exemplify the prevalence of this moiety amongst antibacterial
GyrB / ParE inhibitors (Fig. 1).
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Figure 1. Reported GyrB / ParE inhibitors featuring the N-ethylurea moiety
Molecular design of inhibitors
Employing an in house crystal structure depicting the ATP binding domain of GyrB, we
explored and modeled a number of alternative heterocyclic core scaffolds which, when
coupled to the N-ethylurea side-chain, were predicted to have the potential for potent GyrB
inhibitory activity whilst offering distinct advantages in terms of optimisation opportunities
to compounds 1 – 6. Specifically, the de novo design software SPROUT[14] aided the
identification of putative inhibitors with features complementary to the ATP binding pocket.
Using SPROUT, key interactions within the GyrB ATP binding pocket, specifically
involving Asn-55, Asp-82, Gly-86, Lys-145 and Arg-85 (Figure 2), were selected and an
ethyl urea moiety was positioned so that it would form hydrogen bonding interactions to Asp-
82 and Asn-55 (Figure 2). A variety of small structural fragments were also positioned in the
other selected target sites (for Arg-85 aryl and heteroaryl fragments, for Lys-145 H-bond
acceptors and carboxylates and for Gly-86 H-bond donors) and connected with linker
fragments (consisting of aryl, amide and single carbon atoms) to give a selection of complete
molecules. A number of such design runs were conducted within SPROUT involving
variations in the specific fragments placed at each of the chosen residues and the order in
which these were connected. Following the SPROUT runs the designed molecules were
analysed based on their predicted binding scores and ease of synthesis.
Figure 2. The first stages of de novo design using SPROUT. The ATP binding site of Enterococcus faecalis
GyrB with several target sites selected and an ethyl urea fragment docked into the target sites for Asp-82 and
Asn-55.
From a synthetic viewpoint, the most attractive structure to emerge from this process was
based on a pyridine-3-carboxamide (7) core (Figure 3). Docking of this structure into the
ATP binding site within the protein using AutoDock[15] acted as an independent check and
confirmed that key binding interactions of known importance to GyrB / ParE inhibition
ZRXOGEHPDLQWDLQHG7KHVHLQFOXGHK\GURJHQERQGVWR$VQ$VSDQGDQDU\Oʌʌ
stack interaction with Arg-85 (Enterococcus faecalis GyrB numbering, Figure 4)[16].
Although treated as neutral by AutoDock during the docking process, Arg-85 is likely to be
positively charged under physiological conditions, and therefore interaction of this residue
ZLWKWKHS\ULGLQHULQJPD\EHH[SHFWHGWRKDYHERWKʌʌDQGʌFDWLRQFKDUDFWHU
Figure 3. Simple pyridine-3-carboxamid-6-yl-urea 7 derived using de novo ligand design
Figure 4. Compound 7 docked within the E. faecalis GyrB ATP binding site. Compound 7 is shown as orange
sticks, key residues as grey sticks and polar interactions as dashed black lines.
Synthesis of putative inhibitors
To test the modelling hypothesis, compound 7 was prepared according to the procedure
described in Scheme 1 from commercially available 6-aminonicotinate 8.
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Scheme 1. Reagents and conditions: (a) EtNCO, 1,4-dioxane, 100°C, 18 h, 63%; (b) 2M NaOH (aq), RT, 16 h,
95%; (c) ArNH2, EDC.HCl, HOBT, DMF, RT-40°C, 16 h, 15-70%.
Compound 7 was screened in vitro for GyrB inhibitory activity (ATPase, E. coli) and
minimum inhibitory concentrations (MICs) against S. aureus (ATCC 29213), E. faecalis
(ATCC 29212), Streptococcus pyogenes (ATCC 51339) and Haemophilus influenzae (ATCC
49247) (Table 1).
Table 1.
Comparison of compound 5 with reported GyrB inhibitors
Compound GyrB IC50
(µM)
MIC (µg / mL)
SA EF SP HI
1
a 0.004 0.03 nd nd 1
2
b < 0.75 nd <0.25 nd nd
3
c 0.053 0.5 nd 0.5 nd
4
d 0.041 8 4 8 nd
7 6.0 >256 256 32 >256
E. coli GyrB; SA, S. aureus ATCC 29213; EF, E. faecalis ATCC 29212; SP, S. pyogenes ATCC 51339; HI, H.
influenzae ATCC 49247; nd, not determined;
a
data (Ki) from Charifson et al.[7];
b
data from Haydon et al.
11
;
c
data from Starr et al.[10];
d
data from East et al.[8]
As indicated from inspection of the data in Table 1, although compound 7 synthesised as part
of the present work was 1 – 2 orders of magnitude less potent against GyrB than those
previously reported, this was encouraging given the lower molecular weight / complexity of
this inhibitor. Furthermore, the antimicrobial activity found for this compound, albeit weak,
indicated the potential for optimisation. We therefore elected that our continuing
investigation would focus on further developing these pyridine-3-carboxamides.
C3 position SAR
Our initial SAR investigation concerned variation of the aryl moiety at the pyridyl C3
position of structure 7 and the target molecules were accessed conveniently through coupling
of nicotinic acid 10 with commercially available aromatic amines (Scheme 1, Table 2). We
UHDVRQHGWKDWYDULDWLRQKHUHFRXOGLQFUHDVHWKHLPSRUWDQFHRIWKHʌʌVWDFNLQJZLWK$UJ
Biological data is given in Table 2. In general, substituted phenyl derivatives (entries 11 – 21)
led to improvements in enzyme potency and some MICs were also improved relative to
compound 7. In particular the ortho-chloro compound 12 (GyrB IC50 1.6 µM, MIC 16 µg /
mL SA, EF, SP) demonstrated a good balance between enzyme and cellular potency. Potent
GyrB inhibitors were also identified when the C3 substituent was a 5-membered heterocycle.
Thiazole compounds 25 and 26 have IC50s of 420 nM and 960 nM respectively, though these
compounds did not demonstrate measurable antibacterial activity in the strains tested (Table
2). Compounds 12, 15, 16 and 20, which possessed antibacterial activity against the wild type
strains, were further tested for MICs against a S. aureus GyrB mutant (T173N) and a S.
pyogenes ParE mutant (A53S) respectively. The compounds showed diminished antibacterial
activity relative to that observed for the wild-type, consistent with a target based, dual-
inhibitory mode of action. None of the compounds tested demonstrated antibacterial activity
against the Gram negative organism H. influenzae, highlighting the challenges involved in
targeting Gram negative organisms.
Table 2.
GyrB inhibitory activity and MICs for pyridine-3-carboxamides
Cmpd. R GyrB IC50 MIC (µg / mL)
(µM) SA
SA
(T173N)
EF SP
SP
(A53S)
HI
7 pyridin-3-yl 6.0 >256 nd 256 32 nd >256
11 phenyl 7.7 >64 nd >16 >16 nd >16
12 3-chlorophenyl 1.6 16 >64 16 16 >64 >64
13 2-chlorophenyl 2.1 >64 nd >64 >64 nd >64
14 4-chlorophenyl 3.3 >64 nd >64 >64 nd >64
15 3-flourophenyl 3.0 32 >64 32 32 >64 >64
16 3-methylphenyl 3.4 32 >64 32 32 >64 >64
17 3-cyanophenyl 3.8 >64 nd >64 32 nd >64
18 3-carbamoylphenyl 24.5 >256 nd >256 >256 nd >256
19 3-ethylphenyl 40.4 >256 nd >256 >256 nd >256
20 3,4-bismethoxyphenyl 6.2 >64 >64 32 32 >64 >64
21 5-chloro, 2-
methylphenyl
7.5 >64 nd >64 >64 nd >64
22 pyridin-4-yl 3.5 >64 nd 64 64 nd >64
23 2-methyl pyridin-4-yl 5.3 >64 nd >64 >64 nd >64
24 4-CO2Me pyridin-2-yl 14.0 >64 nd >64 >64 nd >64
25 thiazol-2-yl 0.42 >64 nd >64 >64 nd >64
26 5-CO2H thiazol-2-yl 0.96 >64 nd >64 >64 nd >64
27 cyclohexyl 23.1 >64 nd >64 >64 nd >64
28 4-methylcoumarin-7-yl 8.4 >64 nd >64 >64 nd >64
E. coli GyrB; SA, S. aureus ATCC 29213; EF, E. faecalis ATCC 29212; SP, S. pyogenes ATCC 51339; HI, H.
influenzae ATCC 49247; SA T173N, S. aureus GyrB mutant; SP A53S, S. pyogenes ParE mutant; nd, not
determined.
Variation of the C4 position: Synthesis and SAR
According to our earlier modelling (Fig. 3), a sizeable sub-pocket was predicted such that
substitution at the pyridyl C4 position in structure 7 was highlighted as an option for
structural optimisation. Synthetic routes to these compounds are summarised in Schemes 2 -
5. Our initial route proceeded via 5-iodopyridine 30, which was prepared following
regioselective iodination of 2-amino-4-chloropyridine. A modified Rosenmund-von Braun
reaction[17] installed the carbonitrile functionality as in 31, which was hydrolysed under
aqueous acidic conditions to give tri-substituted nicotinic acid 32. Coupling under standard
conditions with an appropriate aniline led, unexpectedly, to the 6-amino-3,4-bisanilino
intermediate which, when treated with ethylisocyanate, gave pyridin-6-yl-urea 33 (Scheme
2).
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Scheme 2. Reagents and conditions: (a) NIS, DMF, rt, 18h, 60%; (b) Zn(CN)2, Pd(PPh3)4, NMP, 135°C, 2h,
60%; (c) 1:2 c.H2SO4-H2O, 100°C, 18h, 81%; (d) m-toluidine, HOBT, EDC.MeI, DMF, rt, 5h; (e) EtNCO, 1,4-
dioxane, 80°C, 16h, 17% (over 2 steps).
Alternatively, C4 substituted compounds were prepared via dichloronicotinate 36[18] using a
range of synthetic methodologies, as indicated in Schemes 3, 4 and 5. Sequential SNAr at the
C4 and C6 positions of pyridine 36, followed by facile benzyl deprotection using TFA and
triethylsilane, gave 6-amino-4-anilinonicotinate 39. This intermediate was treated with ethyl
isocyanate to give the N-ethylurea 40 as per Scheme 3. Ester hydrolysis under more forcing
conditions than those used previously, preceded synthesis of the target molecules under
standard amide coupling conditions. In an improvement to this synthetic sequence, we
discovered that the N-ethylurea side-chain could be installed directly to C4 functionalised-6-
chloro-nicotinates (i.e. compounds 43 and 44) via a Buchwald-Hartwig type coupling[19].
The target nicotinamides were thus accessed following ester hydrolysis (Scheme 3). A key
improvement was realised upon direct reaction of dichloro compound 36 with N-ethylurea
under the same conditions to give the 4-chloro-pyridin-6-yl-urea intermediate 54 with C6
regioselectivity. Variation at the C4 position was then readily achieved via SNAr, Buchwald-
Hartwig coupling or Suzuki-Miyaura coupling accordingly either following or prior to
nicotinamide synthesis using the previously described conditions (Scheme 4). Further C4-
substituted derivatives were synthesised using a variant synthetic route. Ester hydrolysis of
the 4-chloro-pyridin-6-yl urea intermediate 52 followed by amide coupling using T3P gave 4-
chloro-pyridine carboxamide 90 which was converted to C4 substituted compounds 91 - 93
via SNAr reactions (Scheme 5).
Scheme 3. Reagents and conditions: (a) HC(OEt)3, Ac2O, NH3(aq), 120°C, 2h, 55%; (b) POCl3, 110°C, 2.5h,
79%; (c) m-toluidine, HCl, EtOH, 80°C, 3h, 51%; (d) p-methoxybenzylamine, PhMe, reflux, 72h, 62%; (e)
TFA, Et3SiH, DCM, rt, 4h, 98%; (f) EtNCO, 1,4-dioxane, 100°C, 48h, 43%; (g) 2M NaOH(aq), 75°C, 48h,
90%; (h) EDC.HCl, HOBT, ArNH2, DMF, 40°C, 18h, 35%; (i) ImH, NaH, DMF, 0°C – RT, 34% or N-
methylpiperazine, TEA, EtOH, 0°C, 3h, 80%; (j) Pd(OAc)2, Xantphos, KOtBu, N-ethylurea, 1,4-dioxane, H2O,
100°C, 16h, 79-92%; (k) 2M NaOH (aq), rt or 40°C, 2h, 56-97%; (l) ArNH2, EDC.HCl, HOBT, DMF, rt-40°C,
5-51%.
Scheme 4. Reagents and conditions: (a) Pd(OAc)2, Xantphos, KOt-Bu, N-ethylurea, 1,4-dioxane, H2O, 100°C,
16h, 40%; (b) NaH, NuH, DMF, 0°C - 70°C, 48h, 21-32%, or RNH2, EtOH, reflux, 68-71%, or ArNH2, HCl,
EtOH, 60°C, 16h, 93%; (c) Pd(PPh3)4, ArB(OH)2, 2M Na2CO3(aq), 1,4-dioxane or THF, reflux, 2-16h, 63%; (d)
Pd(OAc)2, Xantphos, KOt-Bu, ArNH2, 1,4-dioxane, H2O, 100°C, 3h; (e) 2M NaOH(aq), rt-70°C, 47%-
quantitative or LiOH (aq), THF, EtOH, 60°C, 3h, 95%; (f) ArNH2, EDC.HCl, HOBT, DMF, rt-40°C, 22-55%.
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36 54 55 R = pyridin-3-yl
56 R = pyrazol-1-yl
57 R = cyclohexylamin-1-yl
58 R = 3-picolylamino
59 R = OPh
60 R = anilin-1-yl
61 R = 4-hydroxyphenylamino
62 R = pyridin-3-yl
63 R = 3-picolylamino
64 R = OPh
65 R = anilin-1-yl
66 R = pyridin3-yl-amino
67 R = 4-hydroxyphenylamino
68 - 88 (See Tables 3 - 6)
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Scheme 5. Reagents and conditions: (a) 2M NaOH(aq), reflux, 80 °C, 18h, 83%; (b) ArNH2, T3P, EtOAc, rt,
18h, 34-57%; (c) ArNH2, HCl, EtOH, 60°C, 16h, 46-83%.
Biological data for the C4 substituted pyridine-3-carboxamides is given in Tables 3 and 4.
Additionally, in order to probe the suitability of these compounds for broad spectrum
therapeutic use, selected compounds were further tested for MICs against an extended panel
of Gram positive (S. epidermidis ATCC 12228, S. pneumonia ATCC 49616), Gram negative
(E. coli ATCC 25922, E. coli N43 efflux knock-out) and mutant (S. aureus T173N GyrB, S.
pyogenes A53S ParE, S. aureus T173N / A53S GyrB-ParE dual mutant) bacterial species.
These additional data are presented in Table 5.
Table 3.
GyrB inhibitory activity and MICs for C4 functionalised pyridine-3-carboxamides
Cmpd. R1 R2 GyrB IC50 (µM) MIC (µg / mL)
SA EF SP HI
33 0.099 1 0.5 32 >64
42 0.098 >64 >64 >64 >64
49 5.14 >64 >64 >64 >64
50 5.66 >64 >64 >64 >64
51 18.0 >64 >64 >64 >64
52 33.2 >64 >64 >64 >64
53 0.55 >64 32 64 >64
68 0.56 >64 64 64 >64
69 1.13 >64 64 64 >64
70 3.02 >64 64 64 >64
71 7.27 >64 64 >64 >64
72 0.81 >64 4 >64 >64
73 2.96 8 1 4 >64
74 2.12 >64 >64 >64 >64
75 0.66 >64 8 8 >64
76 4.81 >64 2 8 >64
E. coli GyrB; SA, S. aureus ATCC 29213; EF, E. faecalis ATCC 29212; SP, S. pyogenes ATCC 51339; HI, H.
influenza ATCC 49247.
As indicated from inspection of the data in Table 3, significant improvements in enzyme
potency and antimicrobial activity were realised upon the addition of a substituted aniline to
the pyridyl C4 position. In particular, compound 33 has an IC50 of 99 nM and MIC of 0.5 µg /
mL against E. faecalis. Thiazol-2-yl nicotinamide 42, being structurally analogous,
demonstrated comparable enzyme inhibition (GyrB IC50 98 nM) but was not antibacterial
within the concentration ranges tested, illustrating the importance of structural modification
on bacterial membrane penetration. Structural departure from an amino aryl substituent at C4
(compounds 49 – 76) led to reduced enzyme potency and antibacterial activity, with the
exception of pyrazol-1-yl compound 73 which, despite having moderate enzyme potency
(GyrB IC50 2.96 µM), retained good activity against Gram positive bacterial species. The 4-
methylpiperazine moiety at C4 (compounds 49 – 52) is conducive with both a reduction in
enzyme inhibitory activity and a loss of antibacterial activity, whilst directly linked aromatic
groups at this position (compounds 53 – 73) resulted in inhibitors with broadly similar
activity profiles to the parent unsubstituted compounds (Table 2). It was evident that a single
atom-linked aromatic ring at the C4 position of the pyridine core was important to inhibitor
efficacy. The reduced potency demonstrated by C4-cyclohexylamino derivative 74, further
confirmed this apparently strict requirement. In order to aid our understanding, compound 33
was modelled within the E. faecalis ATP binding domain (Fig. 5). Again, important polar
contacts were predicted to be maintained and it appeared plausible that ligand ‘pre-
organisation’ through an internal hydrogen bond involving the carbonyl at C3 and the NH at
C4 may explain the improvement in potency.
Figure 5. Compound 33 docked within the E. faecalis GyrB ATP binding site. 33 is shown as orange sticks, key
residues (EF numbering) as grey sticks and predicted polar contacts as dashed lines.
A number of compounds were synthesised to further explore this phenomenon through
preservation of the C4 amino-aryl motif (Table 4). In this instance, simple, unsubstituted
phenyl / pyridine-3-yl moieties were chosen and found to be adequate replacements for the
m-toluidyl group present in compound 33. Compounds featuring the amino-aryl appendage
were predominantly found to have potent GyrB inhibitory activity (IC50s < 500 nM) and
Gram positive antibacterial activity (MICs 0.125 – 2 µg / mL). Tellingly, C4 O-aryl
compound 85, which lacks the ability to form an internal hydrogen bond, is comparatively
inactive and had no antibacterial activity (GyrB IC50 4.9 µM). Para substitution at the C3
aromatic group was found to be well tolerated, with compounds 81 – 83 designed to probe
the solvent exposed area of the binding pocket using morpholine, acetamide and triazole side-
chains respectively. In particular, compound 82 is a highly potent GyrB inhibitor (GyrB IC50
39 nM), presumably forming additional contacts with Lys-145 (Arg-136 E. coli GyrB)
through the acetamide carbonyl oxygen. Incorporating a 3-chlorophenylamine moiety at C3
identified compound 79 as the most potent anti Staphylococcal agent tested here (MIC S.
aureus 0.5 µg / mL). Where MICs against S. aureus were determined in the presence of
plasma proteins (horse serum, compounds 80 – 82, 86), MIC shifts of 4 to 8-fold were
observed, indicating that compounds of this class are not greatly impeded by high plasma-
protein binding (Table 4).
Table 4
GyrB inhibitory activity and MICs for C4 amino-aryl pyridine-3-carboxamides.
Cmpd R1 R2
GyrB IC50
(µM)
MIC (µg / mL)
SA
SA +
HS
EF SP HI
77 phenyl phenyl 0.040 1 nd 0.25 2 >64
78 3-methylphenyl phenyl 0.140 1 nd 0.125 2 >64
79 3-chlorophenyl phenyl 0.150 0.5 nd 0.125 4 >64
80 pyridin-3-yl phenyl 0.170 1 4 0.125 1 >64
81
6-(morpholin-1-
yl)pyridin-3-yl
phenyl 0.110 2 16 0.25 1 >64
82
6-(acetamid-1-
yl)pyridin-3-yl
phenyl 0.039 2 8 0.125 0.5 >64
83
6-(1,2,4-triazol-1-
yl)pyridin-3-yl
phenyl 0.150 >16 nd 0.25 >16 >64
84 3-picolylamin-1-yl phenyl 2.0 >16 nd 0.5 1 >64
85
a phenyl phenyl 4.9 >16 nd >16 >16 >64
86 phenyl pyridin-3-yl 0.43 1 2 0.25 1 >64
87 pyridin-3-yl pyridin-3-yl 0.093 8 nd 0.5 1 >64
E. coli GyrB; SA, S. aureus ATCC 29213; SA + HS, S. aureus + 50% horse serum; EF, E. faecalis ATCC
29212; SP, S. pyogenes ATCC 51339; HI, H. influenzae ATCC 49247. Unless stated, X = NH;
a
X = O; nd, not
determined.
Table 5 details additional biological profiling of the most promising C4 substituted pyridine-
3-carboxamides. Firstly, excellent antibacterial activity was demonstrated against S.
epidermidis and S. pneumonia (MICs 0.125 – 1 µg / mL), confirming the compounds possess
a broad spectrum of Gram positive activity. Furthermore, though none of the compounds
tested showed activity versus E. coli, it is significant that certain compounds (73, 77 and 80)
were active against the efflux knock-out mutant indicating that active efflux plays a role in
the lack of Gram negative activity of this compound class. The MICs for these three
compounds were higher against the efflux-knock out E. coli than against wild type S. aureus
suggesting that they are not able to permeate Gram negative cells as effectively as Gram
positive cells.
Table 5
MICs for selected compounds against GyrB / ParE mutants, additional Gram positive species and E. coli
Cmpd. MIC (µg / mL)
SA
SA
T173N
(GyrB)
SA T173N/
T167N
(GyrB / ParE)
SP
SP
A53S
(ParE)
SE SPn EC
EC
(N43)
73 8 32 >64 4 16 2 1 >64 32
77 1 2 >64 2 16 0.25 1 >64 8
78 1 >64 >64 2 >64 0.5 0.5 >64 >64
79 0.5 1 >64 4 32 0.5 1 >64 >64
80 1 4 >64 1 2 0.25 0.25 >64 8
81 2 >64 >64 1 4 1 0.5 >64 >64
82 2 >64 >64 0.5 2 0.25 0.125 >64 >64
SA, S. aureus ATCC 29213; SA T173N, S. aureus GyrB mutant; SA T173N / T167N, S. aureus dual GyrB /
ParE mutant; SP, S. pyogenes ATCC 51339; SP A53S, S. pyogenes ParE mutant; SE, S. epidermidis ATCC
12228; SPn, S. pneumonia ATCC 49616; EC, E. coli ATCC 25922; EC (N43), E. coli efflux pump mutant.
Finally, mutant data provided useful insights into the mode of action, dual-inhibitory nature
and resistance vulnerability of these compounds. In all cases, MIC shifts were observed
versus GyrB / ParE mutants suggesting bacterial cell death to be target specific rather than
due to promiscuous cell damaging effects. Compounds 33 and 78, whilst potent against wild-
type species, were ineffective against S. aureus and S. pyogenes single-step GyrB and ParE
mutants respectively. Compounds 81 and 82 lost activity against the S. aureus GyrB mutant
but maintained activity against the S. pyogenes ParE mutant. This would suggest GyrB to be
the primary target for these compounds. Pleasingly, compounds 73, 77, 79 and 80 were active
against both GyrB and ParE single-step mutants but lost all antibacterial activity versus the S.
aureus dual GyrB / ParE mutant. The indication is therefore that these compounds are potent
dual inhibitors of GyrB / ParE, are not vulnerable to single-step resistance and would require
a statistically unlikely spontaneous double mutation for resistance to be conferred.
Subsequently a small library of compounds was synthesised with the goal of investigating
alternative substitution at the C4 position (Schemes 4 and 5). Hydroxy- and methoxy-phenyl
derivatives were chosen, as docking indicated that the C4 group would be oriented in a
solvent exposed area, and more polar substituents would be predicted to experience
stabilisation in the water-exposed region. Enzyme inhibition was measured against both GyrB
and ParE enzymes from E. coli and S. aureus and MICs were measured against both S.
aureus and E. coli (Table 6). In keeping with our previous observations, none of the
compounds synthesised showed meaningful activity against the Gram negative species
suggesting that simple variation at the C4 position is insufficient to provide compounds with
Gram negative activity. All compounds showed good inhibitory activity against GyrB and
reasonable activity against ParE, although they were less active against ParE from E. coli
which may offer an additional barrier to activity of these compounds in Gram negative
bacteria.
Table 6
GyrB and ParE inhibitory activity and MICs for C4 amino-aryl pyridine-3-carboxamides
N N
H
N
H
ON
H
O HN R1
N
Compound R1 IC50s (µM) MIC (µg / mL)
GyrB ParE
SA EC SA EC SA EC
88 4-hydroxyphenyl 0.024 0.028 0.086 0.94 8 >64
91 3-hydroxyphenyl nd 0.036 nd 0.78 nd >64
92 2,4-bismethoxyphenyl 0.041 0.046 0.80 42 1 >64
S. aureus and E. coli GyrB; S. aureus and E. coli ParE; SA, S. aureus ATCC 29213; EC, E. coli ATCC 25922;
nd, not determined.
Conclusion
In summary we have reported the discovery, synthesis and an initial SAR study of a novel
series of antibacterial GyrB inhibitors. Through structural optimisation we have developed
the pyridine-3-carboxamide-6-yl-urea core to offer derivatives with excellent GyrB inhibitory
activity and Gram positive antibacterial efficacy. A key activity breakthrough via the
introduction of amino-aryl i.e. NH-aryl functionality at the pyridyl C4 position is reported.
Encouragingly, inhibitors were identified (e.g. compound 80) which demonstrate broad
spectrum Gram positive antibacterial activity, activity against a Gram negative efflux pump
mutant, and activity versus single-step GyrB / ParE mutants. These observations may prove
important in the future therapeutic utility of this compound class. Compounds reported in this
paper have been patented[20]. Further optimisation of compounds in this series is ongoing,
with a focus on modification of physicochemical properties with the hopes of broadening
their spectrum of activity to include Gram negative organisms.
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